CommunityRx - 心血管疾患 (CRx-CVD)
CommunityRx - 心血管疾患: ノースカロライナ州東部の田舎における健康の不平等を軽減するための HealtheRx の実施
The goal of this single arm pre-test post-test design study is to test the impact of providing patients with information about community-based resources to address health-related social needs and cardiometabolic health in rural African American patients. The main question it aims to answer is:
• What is the effectiveness of community resource information on patient self-efficacy to use community resources?
Participants will be given:
- A personalized "HealtheRx" resource with information about community resources related to food, housing, utility support, transportation, and crisis support. The HealtheRx is personalized for patients based on their age and zip code.
- Access to a community resource navigator for support with using the HealtheRx upon request
- 2 text messages with reminders about the HealtheRx and access to the community resource navigator
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
North Carolina
-
Rocky Mount、North Carolina、アメリカ、27801
- OIC Family Medical Center - Fairview
-
Rocky Mount、North Carolina、アメリカ、27804
- OIC Family Medical Center - Happy Hill
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
patient
-
African American
-
age 2 or older
-
Have at least one cardiometabolic condition:
- Overweight (BMI greater than or equal to 25 kg/m^2);
- Obesity (BMI greater than or equal to 30 kg/m^2);
- ICD-9 or 10 diagnostic code for overweight or obesity
- Adult prehypertension (SBP 120 to 129 and DBP greater than 80 mmHg);
- Adult hypertension (SBP greater than or equal to130 or DBP = 80 mmHg);
- Pediatric Prehypertension (SBP or DBP greater than or equal to 90th but <95th percentile)
- Pediatric Hypertension (SBP or DBP greater than or equal to 95th percentile);
- ICD-9 or 10 diagnostic code for hypertension
- Adult and Pediatric Prediabetes (Fasting glucose 100-125 mg/dL or OGTT 140-199 mg/dL)
- Adult and Pediatric Diabetes (FPG greater than or equal to126 mg/dL (7.0 mmol/L) or OGTT greater than or equal to 200 mg/dL (11.1mmol/L) or HgbA1C greater than or equal to 6.5);
- ICD-9 or 10 diagnostic code for diabetes, pre-diabetes or elevated glucose, or gestational diabetes;
- Adult and Pediatric Total cholesterol (>200mg/dL; LDL >130mg/dL; HDL < 35 mg/dL; TG greater than or equal to150mg/dL);
- ICD-9 or 10 diagnostic code for hyperlipidemia
Exclusion Criteria:
- Unable to read, speak or understand English
- Unable to receive text message or email communications
- Living in the same household as someone already enrolled in the CRx-CVD study
- Adults with limited life expectancy (e.g., advanced cancer, end stage liver disease, hospice)
- Adults receiving treatment for cancer
- Adults living in skilled nursing facilities
- Dementia/other significant cognitive impairment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intervention Group
This group will receive the intervention |
CRx-CVD intervention provides participants with a HealtheRx, a tool developed by researchers with personalized listings of community resources with information about housing, food assistance, utility support, transportation and crisis support for patients. A HealtheRx may can be given directly, texted or emailed to patients and caregivers. All patients enrolled in this group will receive the HealtheRx either via text and/or email based on participant preference. Participants will receive contact information for a Community Resource Navigator who can provide support with using the HealtheRx, provide additional resources upon request, and answer any questions the participant may have. Participants will also receive a 2 reminder text messages over 2 months following their initial receipt of the HealtheRx. The SMS messages offer reminders about the HealtheRx and ongoing community resource navigation support. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Participant Self-efficacy for Finding Community Resources
時間枠:Baseline, up to 6 months
|
Change in self-efficacy for finding community resources is measured using one item constructed from Bandura's Self-Efficacy Scale which asks, "How confident are you in your ability to find resources in your community that help you manage your health?" Responses will be assessed on a 5-point Likert scale ranging from 1= "not at all confident" to 5= "completely confident." Lower scores indicate lower levels of confidence, and higher scores indicate higher levels of confidence. |
Baseline, up to 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Participant Knowledge of Community Resources
時間枠:Baseline, up to 6 months
|
Change in participant knowledge of community resources is measured using 10 self-reported survey items adapted and tested in prior CommunityRx studies asking, "For each place that I list, please tell me if you know of places like this in your community: [insert community resource]." The change in the mean number of "yes" responses will be reported. |
Baseline, up to 6 months
|
|
Change in Participant Utilization of Community Resources
時間枠:Baseline, up to 6 months
|
Change in participant utilization of community resources is measured using 10 self-reported survey items adapted and tested in prior CommunityRx studies asking participants "Have you received services from places like this for you or your household in the last 6 months?" The change in the mean number of "yes" responses will be reported. |
Baseline, up to 6 months
|
協力者と研究者
捜査官
- 主任研究者:Gaurav Dave, MBBS, DrPH、Unviersity of North Carolina at Chapel Hill
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 23-0254
- R01HL150909 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
IPD 共有時間枠
Beginning 9 and continuing for 36 months following publication
IPD 共有アクセス基準
Investigator has approved IRB, IEC, or REB and an executed data use/sharing agreement with UNC
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。